LSE - Delayed Quote GBp

Scancell Holdings plc (SCLP.L)

87.60 +0.20 (+0.23%)

As of 2:12:17 PM GMT. Market Open.

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Scancell revs up for Nasdaq listing as cancer vaccine developer prepares phase III melanoma trial

Proactive 24d ago

SCLP.L
+0.23%
NEUP

BLK
Scancell Holdings secures $25m financing as it advances melanoma trial

Proactive 1mo ago

SCLP.L
+0.23%
BLK

SCP.F
Scancell completes up to US$25 million in debt financing, providing optionality alongside equity investment to finance iSCIB1+ phase 3 development

GlobeNewswire 1mo ago

SCLP.L
+0.23%
NEUP

BLK
Scancell secures UK clearance for late-stage melanoma trial

Proactive 2mo ago

SCLP.L
+0.23%
SCP.F

SCNLF
Scancell sees high demand in retail share offer, seals £15.7m from UK investors

Proactive 3mo ago

SCLP.L
+0.23%
NEUP

SCNLF
SMALL-CAP MOVERS: Nasdaq-bound Scancell catches the eye as AIM's headcount falls to 612

Proactive 3mo ago

SCLP.L
+0.23%
NEUP

SCP.F
Neuphoria Therapeutics Agrees to All-Share Takeover by Scancell

PREMIUM
MT Newswires 3mo ago

SCLP.L
+0.23%
NEUP

BLK
Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc

GlobeNewswire 4mo ago

SCLP.L
+0.23%
NEUP
Scancell confirms advanced talks over reverse merger with Neuphoria

Proactive 4mo ago

SCLP.L
+0.23%
NEUP

SCNLF
Scancell's melanoma data keeps widening the gap over standard care as phase III funding race heats up

Proactive 6mo ago

SCLP.L
+0.23%
SCNLF

SCP.F
Scancell receives FDA Fast Track Designation for iSCIB1+ in advanced melanoma and provides data update from its SCOPE Phase 2 study

GlobeNewswire 6mo ago

SCLP.L
+0.23%
Scancell, Eco Buildings, ATOME, Caledonia Mining, Oxford Metrics - Small Cap Snapshot

Proactive 24d ago

ATOM.L

ECOB.L

CMCL

Performance Overview

Return	SCLP.L	FTSE 100 (^FTSE)
YTD	-12.63%	+7.97%
1-Year	-12.18%	+10.34%
3-Year	-29.36%	+43.99%

U.S. markets close in 6h 6m

Scancell Holdings plc (SCLP.L)

Scancell revs up for Nasdaq listing as cancer vaccine developer prepares phase III melanoma trial

Scancell Holdings secures $25m financing as it advances melanoma trial

Scancell completes up to US$25 million in debt financing, providing optionality alongside equity investment to finance iSCIB1+ phase 3 development

Scancell secures UK clearance for late-stage melanoma trial

Scancell sees high demand in retail share offer, seals £15.7m from UK investors

SMALL-CAP MOVERS: Nasdaq-bound Scancell catches the eye as AIM's headcount falls to 612

Neuphoria Therapeutics Agrees to All-Share Takeover by Scancell

Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc

Scancell confirms advanced talks over reverse merger with Neuphoria

Scancell's melanoma data keeps widening the gap over standard care as phase III funding race heats up

Scancell receives FDA Fast Track Designation for iSCIB1+ in advanced melanoma and provides data update from its SCOPE Phase 2 study

Scancell, Eco Buildings, ATOME, Caledonia Mining, Oxford Metrics - Small Cap Snapshot